See the DrugPatentWatch profile for dupixent

Dupixent, a medication used to treat various allergic conditions, experienced significant success in Q4 2020. While the specific sales figures for regional sales are not publicly available, there are indications that regional sales played a role in this success.

Dupixent is a product of Sanofi and Regeneron Pharmaceuticals, and its Q4 2020 sales were $1.35 billion, a 35% increase from the previous year [1]. This success can be attributed to several factors, one of which is regional sales.

According to a DrugPatentWatch.com report, Dupixent has been successful in expanding its market presence in various regions [2]. For instance, in October 2020, Dupixent received approval from the European Commission for additional indications, which likely contributed to its Q4 2020 success [3].

Moreover, Dupixent's growth in regions outside the United States has been significant. In Q3 2020, international sales of Dupixent increased by 63% [4]. This trend likely continued into Q4 2020, further boosting the drug's overall sales.

In conclusion, while specific regional sales figures for Dupixent in Q4 2020 are not available, the drug's overall success in this period can be linked to its expansion in various regions. This is supported by Dupixent's approval for additional indications in Europe and its growing sales in international markets.

Sources:
[1] "Sanofi and Regeneron Announce Fourth-Quarter and Full-Year 2020 Sales". Sanofi, February 4, 2021. https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-04-09-00-00--sanofi-and-regeneron-announce-fourth-quarter-and-full-year-2020-sales.
[2] "Dupixent (Dupilumab)". DrugPatentWatch.com. https://www.drugpatentwatch.com/drugs/dupixent.
[3] "Dupixent receives European Commission approval for additional indications in atopic dermatitis and chronic rhinosinusitis with nasal polyps". Regeneron Pharmaceuticals, Inc., October 2, 2020. https://investor.regeneron.com/news-releases/news-release-details/dupixent-receives-european-commission-approval-additional.
[4] "Regeneron Reports Third-Quarter 2020 Financial and Operating Results". Regeneron Pharmaceuticals, Inc., October 29, 2020. https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2020-financial-and-operating.